Young Ah Lee1, Hae Woon Jung, Hwa Young Kim, Hoonsung Choi, Hyun-Young Kim, J Hun Hah, Do Joon Park, June-Key Chung, Sei Won Yang, Choong Ho Shin, Young Joo Park. 1. Department of Pediatrics (Y.A.L., H.W.J., H.Y.K., S.W.Y., C.H.S.), Seoul National University Children's Hospital, Seoul National University College of Medicine, Seoul, 110-769, Korea; and Departments of Internal Medicine (H.C., D.J.P., Y.J.P.), Nuclear Medicine (J.J.-K.C.), Surgery (H.-Y.K.), and Otorhinolaryngology and Cancer Research Institute (J.H.H.), Seoul National University College of Medicine, Seoul 110-744, Korea.
Abstract
CONTEXT: Large-sample studies with long-term follow-up data are limited for pediatric patients with thyroid cancer. OBJECTIVE: Secular changes in clinicopathological characteristics and outcomes in pediatric patients with thyroid cancer were investigated and compared with those of adults. DESIGN AND PATIENTS: A retrospective review of 150 pediatric patients with thyroid cancer managed between 1980 and 2013 was conducted. The long-term outcomes of 124 patients followed up for 12 months or longer were evaluated. Predictors of recurrence-free survival (RFS) in pediatric patients with papillary thyroid cancer (ped-PTC group) were compared with those of 3071 adult patients. RESULTS: The proportion of small tumors (<1 cm) increased from 9.0% before 2010 to 36.8% after 2010 (P < .001); however, neither pathological presentations such as multifocality, extrathyroidal extension (ETE), lymph node (LN) metastasis, or lung metastasis nor the RFS rate changed over time. The 5- and 10-year recurrence rates were 14.5% and 34.4% in pediatric patients, respectively. In respective analyses of the ped-PTC group and patients of all ages with papillary thyroid cancer (all ages group), the rates of ETE, LN metastasis, and lung metastasis were higher with younger age (all P for trend <.05). RFS was lower in the pediatric than the adult patients aged 20-54 years (P < .005) and was comparable with that of older patients (≥ 55 y). Only tumor multifocality and size predicted recurrence in the ped-PTC group (P < .05), whereas LN metastasis and ETE also predicted recurrence in the all-ages group (P < .01). Among patients in the all-ages group with multifocal tumors, pediatric patients had the lowest RFS (P < .05). CONCLUSIONS: The pathological characteristics and recurrence rates of pediatric thyroid cancer have not changed over 33 years. Although younger patients present with more advanced disease, multifocality rather than age at diagnosis predicted recurrence. Recurrence was higher in pediatric than adult patients with multifocal papillary thyroid cancer.
CONTEXT: Large-sample studies with long-term follow-up data are limited for pediatric patients with thyroid cancer. OBJECTIVE: Secular changes in clinicopathological characteristics and outcomes in pediatric patients with thyroid cancer were investigated and compared with those of adults. DESIGN AND PATIENTS: A retrospective review of 150 pediatric patients with thyroid cancer managed between 1980 and 2013 was conducted. The long-term outcomes of 124 patients followed up for 12 months or longer were evaluated. Predictors of recurrence-free survival (RFS) in pediatric patients with papillary thyroid cancer (ped-PTC group) were compared with those of 3071 adult patients. RESULTS: The proportion of small tumors (<1 cm) increased from 9.0% before 2010 to 36.8% after 2010 (P < .001); however, neither pathological presentations such as multifocality, extrathyroidal extension (ETE), lymph node (LN) metastasis, or lung metastasis nor the RFS rate changed over time. The 5- and 10-year recurrence rates were 14.5% and 34.4% in pediatric patients, respectively. In respective analyses of the ped-PTC group and patients of all ages with papillary thyroid cancer (all ages group), the rates of ETE, LN metastasis, and lung metastasis were higher with younger age (all P for trend <.05). RFS was lower in the pediatric than the adult patients aged 20-54 years (P < .005) and was comparable with that of older patients (≥ 55 y). Only tumor multifocality and size predicted recurrence in the ped-PTC group (P < .05), whereas LN metastasis and ETE also predicted recurrence in the all-ages group (P < .01). Among patients in the all-ages group with multifocal tumors, pediatric patients had the lowest RFS (P < .05). CONCLUSIONS: The pathological characteristics and recurrence rates of pediatric thyroid cancer have not changed over 33 years. Although younger patients present with more advanced disease, multifocality rather than age at diagnosis predicted recurrence. Recurrence was higher in pediatric than adult patients with multifocal papillary thyroid cancer.
Authors: Seo Young Sohn; Young Nam Kim; Hye In Kim; Tae Hyuk Kim; Sun Wook Kim; Jae Hoon Chung Journal: Endocrine Date: 2017-08-18 Impact factor: 3.633
Authors: Kwangsoon Kim; Won Woong Kim; Jung Bum Choi; Min Jhi Kim; Cho Rok Lee; Jandee Lee; Sang-Wook Kang; Kee-Hyun Nam; Woong Youn Chung; Jong Ju Jeong Journal: Ann Surg Treat Res Date: 2018-09-28 Impact factor: 1.859
Authors: Soo Young Kim; Hyeok Jun Yun; Hojin Chang; Seok-Mo Kim; Soyoung Jeon; Sujee Lee; Yong Sang Lee; Hang-Seok Chang; Cheong Soo Park Journal: Front Oncol Date: 2022-04-26 Impact factor: 5.738
Authors: Joon Ho Jang; So Hyun Park; Kyung Soon Cho; Won Kyung Cho; Young Jin Suh; Byung Kyu Suh; Dae Kyun Koh Journal: Ann Pediatr Endocrinol Metab Date: 2018-06-20
Authors: Agnes Stephanie Harahap; Desty Gusti Sari; Marini Stephanie; Alvita Dewi Siswoyo; Litta Septina Mahmelia Zaid; Diani Kartini; Maria Francisca Ham; Tri Juli Edi Tarigan Journal: J Thyroid Res Date: 2022-01-11